Living to 100 is still rare. Living to 120 is extraordinary. But what about 150?
A Chinese biotech company says that kind of lifespan may eventually be within reach, and the product at the center of its claim sounds surprisingly ordinary: a pill derived from grape seeds.
The company, Lonvi Biosciences, is developing a longevity supplement based on a compound called procyanidin C1, or PCC1. Its CEO has gone so far as to call the approach the “Holy Grail,” while the possibility of humans living to 150 has helped the story spread rapidly online.
It sounds like the kind of anti-aging promise that would be easy to dismiss. Except there is real science behind PCC1.
In a 2021 study published in Nature Metabolism, researchers found that the compound could target senescent, or “zombie,” cells and extend survival in old mice. These damaged cells accumulate as we age and have become an increasingly important target in longevity research.
But getting from longer-lived mice to humans celebrating their 150th birthdays requires some enormous leaps. There are no human trials showing that PCC1 extends lifespan, and since the original excitement, another issue has emerged that makes the evidence worth looking at much more carefully.
So, how much of the 150-year promise is grounded in longevity science, and how much is getting ahead of what researchers actually know?
What Zombie Cells Actually Are
Senescent cells – sometimes called zombie cells – stop replicating but also resist the normal process of programmed self-destruction. Researchers at Cedars-Sinai describe them as cells that accumulate steadily in tissues as the body ages. They develop what scientists call the senescence-associated secretory phenotype, or SASP – a pattern of releasing inflammatory signals into surrounding tissue that can damage neighboring healthy cells and drive dysfunction throughout the body.
This process fuels chronic inflammation, tissue dysfunction, and age-related diseases including cardiovascular disease, dementia, and neurodegeneration. The practical implication is that zombie cells may be a root cause of many conditions that make people sick and frail in old age. Selectively removing them, or suppressing the damage they cause, could potentially delay or prevent those conditions from developing.
Senolytics are compounds designed to do exactly that – selectively destroy senescent cells. A related category, senomorphics, works differently, suppressing the harmful inflammatory signals without killing the cells outright. Both strategies are being actively investigated by researchers around the world, targeting biology that appears to sit upstream of a wide range of age-related diseases.
The PCC1 Mouse Data
The 2021 paper that gave Lonvi its scientific foundation was published in Nature Metabolism. Researchers screened a library of natural products to identify candidates with senotherapeutic activity, and PCC1 – isolated from grape seed extract – stood out among them. The paper reported that the compound increases the healthspan and lifespan of mice through its action on senescent cells.
The mechanism is dual-action and dose-dependent. At lower concentrations, PCC1 acts as a senomorphic, tamping down the inflammatory SASP signals. At higher concentrations, it flips into senolytic mode, selectively pushing senescent cells toward self-destruction. Intermittent administration to irradiated, senescent cell-implanted, or naturally aged old mice produced improvements in physical function and extended survival.
Lonvi reports that in their mouse trials, the treatment increased overall lifespan by 9.4 percent and extended life by 64 percent from the first day of treatment. That second number – the 64 percent – is where much of the 150-year extrapolation originates. The figure comes from mice that had already reached old age; they lived significantly longer after treatment began, relative to their remaining expected lifespan. Scaling that percentage gain to a human lifespan and landing on 150 is a creative mathematical exercise, but it has no scientific foundation in human data.
A Complication the Headlines Left Out
The 2021 Nature Metabolism paper became the scientific backbone of the entire PCC1 longevity story. In February 2026, an Editorial Expression of Concern for the paper was published in Nature Metabolism (volume 8, page 757). The concern relates to a specific figure in the paper – Figure 6b – where a mouse image appears highly similar to a different mouse image in a separate figure. The authors were asked to produce the underlying raw data to resolve the issue and were unable to do so. The journal explicitly advised readers to interpret those data with caution. Two of the study’s authors agreed to the Expression of Concern; the others did not respond to correspondence from the journal or publisher.
An Expression of Concern is not a retraction. It means the journal has identified a credibility problem significant enough to alert readers, but the investigation is either ongoing or unresolved. For a study this central to a commercial longevity product, it matters. Lonvi’s CTO cited this very research as justification for the 150-year claim. The claim was already a stretch from the data. The integrity concern makes the foundation shakier still.
Read More: Body’s Most Mysterious Organ May Play a Key Role in Longevity and Cancer
How Far Senolytics Have Actually Come in Humans
Early-phase clinical trials evaluating senolytic compounds for conditions linked to aging are now underway, including Alzheimer’s disease and idiopathic pulmonary fibrosis. The most studied senolytic combination in humans is dasatinib plus quercetin. A 2019 Mayo Clinic study published in EBioMedicine found that this pairing reduced senescent cell burden in people with diabetic kidney disease within 11 days. A 2025 pilot study published in eBioMedicine evaluated the same combination in older adults at risk for Alzheimer’s disease, with participants taking 100 mg of dasatinib and 1,250 mg of quercetin for two days every two weeks over 12 weeks. These are early-stage, small-sample studies – but they represent actual human data, which PCC1 still largely lacks.
For PCC1 specifically, the human research is limited. A registered clinical trial is evaluating PCC1 for skin rejuvenation in healthy women aged 45 to 65 over 12 weeks – a modest, cosmetic endpoint that has nothing to do with lifespan extension. No human trials have tested PCC1 for longevity outcomes.
Mice and humans share biology, but they differ in metabolic rate, immune function, disease mechanisms, and dozens of other variables that affect how compounds behave. Any extrapolation from a mouse study to humans is highly speculative. That’s not a reason to dismiss the research – it’s a reason to wait for human data before drawing conclusions.
Senolytics also carry an underappreciated complication: some senescent cells contribute to wound healing while others cause harm. Researchers are still working out which senescent cells are harmful, which are beneficial, and how to target one without disturbing the other.
The 150-Year Number Has No Basis in Human Evidence
The verified record for any individual remains Jeanne Calment’s 122 years, set in 1997. No person in recorded history has lived to 130. Getting from 122 to 150 would require not just slowing aging but reversing it in ways that current science cannot approach, let alone guarantee from a grape-seed pill taken three days a month.
China has made healthy aging a core national strategy priority during its 14th Five-Year Plan period, and that political and economic context matters. Longevity startups in China are operating inside a well-funded ecosystem where bold claims attract investment and attention. Lonvi is part of that ecosystem. The science it’s built on – even before the Expression of Concern – was promising mouse-level biology, not human evidence of lifespan extension.
The American Council on Science and Health has noted that promoting PCC1 supplements without any evidence from human clinical trials is jumping the gun. The field of senolytic therapy is a legitimate and active area of research, with real scientists running real trials. No pill currently exists that can extend human life to 150. The 2026 integrity concern around the foundational study makes that gap wider.
Read More: Survive Until 2050, and You Might Live Forever, Experts Say
The Bottom Line
PCC1 is more interesting than the typical ingredient behind an anti-aging supplement. The original Nature Metabolism study identified a plausible biological mechanism and reported improved health and survival in mice by targeting senescent cells. And senolytics more broadly remain a legitimate area of aging research.
But none of that demonstrates that PCC1 can make humans live longer, much less to 150. Human research on the compound remains extremely limited, and no clinical trial has tested whether it extends human lifespan.
There is also the unresolved problem with the research that helped launch the excitement. In 2026, Nature Metabolism published an Editorial Expression of Concern over part of the 2021 study after questions were raised about an image and the underlying raw data could not be produced. An Expression of Concern is not a retraction, but it is a reason to interpret the affected findings cautiously.
That leaves an enormous gap between what has actually been demonstrated and the claim now circulating online.
Scientists may eventually find ways to slow aspects of biological aging, and targeting senescent cells could turn out to be one piece of that puzzle. PCC1 may even have a role to play. But right now, the intriguing part of this story isn’t that scientists have invented a pill that can make people live to 150.
It’s that they’re beginning to learn how some of the cellular processes behind aging might be manipulated at all.
Disclaimer: The author is not a licensed medical professional. The information provided is for general informational and educational purposes only and is based on research from publicly available, reputable sources. It is not intended to constitute, and should not be relied upon as, medical advice, diagnosis, or treatment. Always consult a licensed physician or other qualified healthcare provider regarding any medical condition, symptoms, or medications. Do not disregard, avoid, or delay seeking professional medical advice or treatment because of information contained herein.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Why Biohacks Are a False Promise — and What Actually Works for Longevity